Zofenopril after anterior myocardial infarction

Klaus Mörike, Gerd Mikus, Paul A. Gurbel, Christopher M. O'connor, G. Muqtada Chaudhry, Neenoofar Haneef, Claudio Borghi, Ettore Ambrosioni, Bruno Magnani

Research output: Contribution to journalLetter

Abstract

To the Editor: In the study of zofenopril reported by Ambrosioni et al. (Jan. 12 issue),1 the subgroup analysis (their Table 5) showed beneficial effects in patients concomitantly treated with calcium-channel blockers during the six-week treatment period. During the observation period, significantly more patients in the zofenopril group (21.1 percent) than in the placebo group (15.9 percent) received calcium-channel blockers (P = 0.02, as shown in their Table 4). This difference raises the possibility that the favorable outcome in the zofenopril group may have been due in part to the calcium-channel blockers. Indeed, the administration of calcium-channel blockers after acute.

Original languageEnglish (US)
Pages (from-to)1715-1716
Number of pages2
JournalNew England Journal of Medicine
Volume332
Issue number25
DOIs
StatePublished - Jun 22 1995

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Zofenopril after anterior myocardial infarction'. Together they form a unique fingerprint.

  • Cite this

    Mörike, K., Mikus, G., Gurbel, P. A., O'connor, C. M., Chaudhry, G. M., Haneef, N., Borghi, C., Ambrosioni, E., & Magnani, B. (1995). Zofenopril after anterior myocardial infarction. New England Journal of Medicine, 332(25), 1715-1716. https://doi.org/10.1056/NEJM199506223322513